linjc16/ctgov huggingface dataset:
Diuretic Efficacy of Dexamethasone in Heart Failure

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether glucocorticoids have potent diuretic effects in patients with congestive heart failure.

Detailed Description
-----------------
Glucocorticoids are known to have pronounced physiological effects in the kidney. Conventional teaching dictates that it should be used with caution in patients with congestive heart failure due to its fluid and sodium retention effects. Surprisingly, despite the widespread prevalence of this belief within the medical community, there are few data to support it. In fact, several small animal studies have documented its striking diuretic effects due to increased renal plasma flow and glomerular filtration rate without changes in the glomerular filtration fraction. We design this study to determine whether glucocorticoids have a potent diuretic effect in patients with heart failure.

Official Title
-----------------
Diuretic Efficacy of Dexamethasone in Congestive Heart Failure Patients

Conditions
-----------------
Heart Failure, Congestive

Intervention / Treatment
-----------------
* Drug: dexamethasone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Congestive heart failure patients due to any cause Patients with normal cortical function Congestive heart failure patients who are on diuretic therapy Clinically stable and body weight maintained the same for at least 3 days without signs of fluid retention Exclusion Criteria: Patient refusal Signs of infection

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: dexamethasone|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| urine volume |  |  | 
| urine electrolyte excretion (urine sodium, urine potassium, urine chloride), and urine creatinine. |  |  | 
| serum electrolyte (serum sodium, serum potassium, serum chloride), serum creatinine, serum urea, serum uric Acid. |  |  | 
| fractional sodium excretion |  |  | 
| glomerular filtration rate (calculated by Cockroft and Gault formula). |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
dexamethasone, diuretic, congestive heart failure
Solitaire Aneurysm Remodeling Registry

Study Overview
=================
Brief Summary
-----------------
The objective of the registry is to evaluate the effectiveness and performance of the Solitaire Neurovascular Remodeling Device when used with embolic coils in the treatment of intracranial aneurysms.

Official Title
-----------------
Prospective Multi-center, Single-arm Registry to Evaluate the Efficacy of the Solitaire AB Neurovascular Remodeling Device in the Treatment of Wide-neck Intracranial Aneurysms

Conditions
-----------------
Intracranial Saccular Aneurysm, Either Rupture or Unruptured, Wide Neck Aneurysm

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Confirmed diagnosis of intracranial saccular aneurysms, either ruptured or unruptured Aneurysm requires current treatment with coils and a stent or aneurysm hs been previously treated with coils, but no prior placement of a stent. Aneurysm has a wide neck defined as having a neck equal to or greater than 4mm or a dome-to-neck ratio of <2. Patient is 18 years or older. Patient has a Hunt & Hess score of III or less. Exclusion Criteria: Patient has a fusiform or dissecting aneurysm type. Patient is contraindicated for either heparin or anti-platelet therapy. Patient has severe allergy to IV contrast medium. Patient has a known hypersensitivity to nickel-titanium.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Stable Stent placement with complete coverage across the aneurysm neck with parent artery patency |  | Six months post-implant | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Intracranial aneurysms, Wide neck aneurysms
PET/CT in Psoriatic Arthritis

Study Overview
=================
Brief Summary
-----------------
When patients with psoriasis develop joint pain, it is often hard to decide whether or not the pain is due to psoriatic arthritis (PsA). At this time, doctors use information from the history and physical exam to determine the diagnosis. X-rays, magnetic resonance imaging (MRI) and ultrasound have been used to help with the diagnosis but all three have limitations. A newer imaging technique, whole body Positron Emission Tomography/Computed Tomography (PET/CT) uses the idea that inflammatory cells take up sugar to locate inflammation in the body. Because patients with PsA have inflammatory cells in their joints and tendons, this type of scan allows the physician to take a picture of the whole body and locate inflammation. The investigators have found that some patients with psoriasis (but without arthritis) have inflammation in joints and tendons even before the patient has symptoms. In this study, the investigators will explore how well PET/CT works for assessing inflammation in patients with PsA. This would be a very exciting tool that could be used to find and treat inflammation before it causes damage or pain.

Official Title
-----------------
FDG-PET/CT in the Diagnosis and Monitoring of Psoriatic Arthritis

Conditions
-----------------
Psoriatic Arthritis

Intervention / Treatment
-----------------
* Radiation: FDG-PET/CT scan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18-80, active psoriatic arthritis (joint or enthesis inflammation) Exclusion Criteria: Diabetes, pregnant, no active PsA

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Psoriatic arthritis<br> | Radiation: FDG-PET/CT scan<br>* FDG-PET/CT is a type of imaging used currently to look for cancer. We are using it to look at inflammation within the joints.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Primary outcome is inflammation as measured by SUVmax and metabolic volumetric product in the joints and entheses. |  | At the discretion of the PI | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation of local inflammation in joints and enthesis with systemic inflammatory markers including IL6 and high sensitivity CRP. |  | At the discretion of the PI |
CERTAS Programmable Valve Registry

Study Overview
=================
Brief Summary
-----------------
Post-Market Clinical Follow-up Registry of Patients with CODMAN CERTAS Plus Programmable Valves.

Detailed Description
-----------------
The CODMAN CERTAS Plus Programmable Valve is a single use implantable device designed for shunting cerebrospinal fluid (CSF) for the treatment of hydrocephalus. The clinical investigation specifically aims to collect data on the performance measures outlined below. Data will be collected per standard of care, given the nature of the clinical investigation to capture real world data (registry); timing, frequency, and methodology of assessing the performance outcomes may therefore differ per center, subject, and/or visit. 1) Improvement of the following symptoms related to hydrocephalus: Gait disturbances; Spatial impairment; Cognitive abilities; Urinary incontinence; Pain caused by headaches; Visual acuity.

Official Title
-----------------
Post-Market Clinical Follow-up Registry of Patients With CODMAN CERTAS Plus Programmable Valves

Conditions
-----------------
Hydrocephalus, NPH (Normal Pressure Hydrocephalus), IIH - Idiopathic Intracranial Hypertension

Intervention / Treatment
-----------------
* Device: CODMAN CERTAS Programmable Valves


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients (18-80 years old at time of enrollment) undergoing implantation of the CODMAN CERTAS Plus Programmable Valve according to the device label. Patients willing and able to understand and sign informed consent. Exclusion Criteria: N/A

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| CODMAN CERTAS Programmable Valves<br>CODMAN CERTAS Plus Programmable Valve, CODMAN CERTAS Plus Small Inline Programmable Valve, and CODMAN CERTAS Plus Right Angle Programmable Valve. | Device: CODMAN CERTAS Programmable Valves<br>* Patients will undergo implantation of the CODMAN CERTAS Plus Programmable Valve according to the device label.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Performance Endpoints | The change from baseline for the following symptoms related to hydrocephalus, e.g. gait disturbances, spatial impairment, cognitive abilities, urinary incontinence, pain caused by headaches and visual acuity. | 1 month, 3 months, 6 months, 12 months, 24 months, and 36 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Device Deficiencies | Incidence and nature of device deficiencies | 1 month, 3 months, 6 months, 12 months, 24 months, and 36 months |
Clinical Trial of Sipjeondaebo-tang on Fatigue of Breast Cancer Patients

Study Overview
=================
Brief Summary
-----------------
This is a pilot study that investigate efficacy and safety of Sipjeondaebo-tang on fatigue of patients with breast carcinoma receiving chemotherapy.

Official Title
-----------------
Sipjeondaebo-tang for Alleviating Fatigue Measured by Brief Fatigue Inventory and EORTC-QLQ-C30, BR23 Score Change Among Patients With Breast Carcinoma Receiving Chemotherapy

Conditions
-----------------
Breast Carcinoma

Intervention / Treatment
-----------------
* Drug: Sipjeondaebo-tang


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: men and women aged over 18 years patients who have histologically or cytologically confirmed breast tumor patients who applicable AC(doxorubicin + cyclophosphamide) ECOG score 0 to 2 Exclusion Criteria: patient impossible to orally intake patient with dementia, delirium and depression patient suffering from diseases like chronic hepatitis B, C or hepatocirrhosis severe liver disability (3-fold the normal high range value for ALT, AST) patient who has diabetes not controlled by diet, hypertension, hyperthyroidism, severe systemic disease use of other investigational products within the past 30 days hypersensitivity to investigational product others who are judged not to be appropriate to study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: A group<br>Take Sipjeondaebo-tang on 0 2 week, 3 5 week of clinical trial period, total of 4 weeks | Drug: Sipjeondaebo-tang<br>* Herbal medicine which is a compound of 10 herbs.<br>* Other names: Deciten granule;|
| Experimental: B group<br>Take Sipjeondaebo-tang on 6 8 week, 9 11 week of clinical trial period, total of 4 weeks | Drug: Sipjeondaebo-tang<br>* Herbal medicine which is a compound of 10 herbs.<br>* Other names: Deciten granule;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Brief Fatigue Inventory change |  | 0-5 week | 
| Brief Fatigue Inventory change |  | 6-11 week | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| EORTC-QLQ-C30 change |  | 0-5 week, 6-11 week | 
| EORTC-QLQ-BR23 change |  | 0-5 week, 6-11 week |
Evaluation of the Quality of the Transfusion Practice at Rigshospitalet, Copenhagen University Hospital

Study Overview
=================
Brief Summary
-----------------
The purpose is to evaluate and improve transfusion practice

Conditions
-----------------
Hemorrhage, Blood Transfusions

Intervention / Treatment
-----------------
* Behavioral: Transfusion practice


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Hospitalized at Rigshospitalet, Copenhagen University Hospital Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 0 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Transfusion practice|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Specificity Study of Diagnostic for Early Detection of Dengue Infection

Study Overview
=================
Brief Summary
-----------------
This study assesses the specificity of DENV Detect™ NS1 ELISA versus standard reference tests (e.g. PCR or viral culture) for dengue diagnosis in the US. DENV Detect™ NS1 ELISA serves as an aid in the clinical laboratory diagnosis of early stages of Dengue infection in patients with clinical symptoms consistent with Dengue infection. This test is intended to be used on sera obtained within the first 7 days of symptoms. DENV Detect™ NS1 ELISA and rapid test results (positive or negative) must be confirmed by testing with a reference standard test. This study will use archived, leftover human serum samples that have been sequentially collected from areas non-endemic for Dengue infection. Each specimen must have been collected within the first 7 days of symptoms, and must be accompanied by clinical data demonstrating that the individual had symptoms consistent with Dengue infection. The samples will have no personally identifiable information. ELISAs and reference tests will be performed by different operators who are laboratory staff members. These staff members, blinded to each other's results, will evaluate the samples from each method independently.

Official Title
-----------------
Determination of Estimated Specificity of DENV Detect NS1 ELISAs

Conditions
-----------------
Infectious Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All age groups and both sexes. Serum samples collected within 1- 7 days of onset of symptoms consistent with Dengue virus infection. Information must be available about symptoms, age, and sex of patients from which samples are collected. Exclusion Criteria: Any sample(s) with linked personal identifiers or any sample for which personal information can be discovered will be excluded.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of subjects with negative result |  | one day |
Self-Assembled Skin Substitute for the Treatment of Epidermolysis Bullosa

Study Overview
=================
Brief Summary
-----------------
Single patient study. Patient diagnosed with dystrophic epidermolysis bullosa presenting chronic open wounds that are not responding to dressings, topical preparations (antimicrobials, antibiotics) and systemic agents (anti-inflammatory antibacterials). The Self-Assembled Skin Substitutes will be used to cover wounds.

Official Title
-----------------
SASS 3: Self-Assembled Skin Substitute (SASS) for the Treatment of Epidermolysis Bullosa

Conditions
-----------------
Epidermolysis Bullosa Dystrophica

Intervention / Treatment
-----------------
* Biological: SASS


Participation Criteria
=================
Eligibility Criteria
-----------------
This clinical trial was custom designed for one patient
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Interventional Model Description: n-of-one
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: SASS<br>SASS applied on chronic skin wounds as skin graft | Biological: SASS<br>* SASS applied on chronic skin wounds as skin graft<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percent reduction in wound surface area | Clinical assessment | 2 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Graft failure | Clinical assessment | 2 weeks | 
| Number of subsequent re-transplantation | Number | 3 years | 
| Time (in weeks) to 50% reduction in the surface area of the wounds; | Clinical assessment | 3 years | 
| Time (in weeks) to complete healing | Clinical assessment | 3 years | 
| Changes in pain scores | 10 point visual analog scale where 0 is none and 10 the worst pain | 3 years | 
| Changes in itch scores where 0 is none and 10 the worst itch | 10 point scale | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Tissue Engineering, Skin Substitute
Study of Staphylococcus Aureus Colonization of the Posterior Nasal Cavity in Patients Undergoing Otorhinolaryngologic Surgery

Study Overview
=================
Brief Summary
-----------------
Staphylococcus aureus nasal carriage is a major risk factor of infection with this bacterium. Staphylococcus aureus colonization of the posterior nasal cavity is still misunderstood. This study is aimed at evaluating the relationship between Staphylococcus aureus strains colonizing the vestibulum nasi, the sphenoethmoidal recess and the nasopharynx.

Official Title
-----------------
Study of Staphylococcus Aureus Colonization of the Posterior Nasal Cavity in Patients Undergoing Otorhinolaryngologic Surgery. A Monocentric Study

Conditions
-----------------
Staphylococcal Infections

Intervention / Treatment
-----------------
* Other: Staphylococcus aureus carriage


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergoing otorhinolaryngologic surgery, unknown Staphylococcus aureus carriage state Patient affiliated to French Social Security Written consent Exclusion Criteria: Antibiotherapy or infectious episode during the month prior enrollment coagulation disorder neoplasia of the nasal cavity

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Patient undergoing otorhinolaryngologic surgery<br>Staphylococcus aureus carriage is measured in the vestibulum nasi and posterior nasal cavity. Posterior nasal cavity is measured during endoscopic procedure. | Other: Staphylococcus aureus carriage<br>* Vestibulum nasi and posterior nasal cavity sampling with swabs and posterior nasal cavity sampling by endoscopic procedure during otorhinolaryngologic surgery<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of patients with staphylococcus aureus carriage in the posterior nasal cavity |  | Day 1 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of patients with staphylococcus aureus carriage in the vestibulum nasi |  | Day 1 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
staphylococcal infections, nasal carriage, nasal cavity, Staphylococcus aureus